
|Articles|May 12, 2022
Daily Medication Pearl: Delafloxacin (Baxdela)
Author(s)Saro Arakelians, PharmD
Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.
Advertisement
Medication Pearl of the Day: Delafloxacin (Baxdela)
Indication: Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated in adults for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.
Insight:
- Dosing: Administer delafloxacin for injection 300 mg by intravenous (IV) infusion over 60 minutes, every 12 hours, or a 450-mg delafloxacin tablet orally every 12 hours for 5 to 14 days total duration.
- Dosage forms: For Injection 300 mg of delafloxacin (equivalent to 433 mg delafloxacin meglumine) as a lyophilized powder in a single dose vial for reconstitution and further dilution before IV infusion.
- Adverse events: Most common adverse reactions (incidence ≥ 2%) are nausea, diarrhea, headache, transaminase elevations and vomiting.
- Mechanism of action: Delafloxacin is an antibacterial drug.
- Manufacturer: Melinta Therapeutics
Reference
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
3
Workforce Preparation for Fall Immunization Season Starts Now
4
Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment
5






































































































